Health Care Stocks Mixed as NYSE Health Care Index Edges Up

Written by Emily J. Thompson, Senior Investment Analyst

OTLK-2.17%

HOTH-2.88%

IRWD-0.77%

Source: Yahoo Finance

Updated: Jan 02 2026

0mins

Source: Yahoo Finance

Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.

OTLK

$0.4972+Infinity%1D

Analyst Views on OTLK

Wall Street analysts forecast OTLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OTLK is 3.83 USD with a low forecast of 0.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.508

Low

0.50

Averages

3.83

High

10.00

Current: 0.508

Low

0.50

Averages

3.83

High

10.00

H.C. Wainwright

Neutral

maintain

2026-01-02

Reason

H.C. Wainwright

Price Target

AI Analysis

2026-01-02

maintain

Neutral

Reason

H.C. Wainwright lowered the firm's price target on Outlook Therapeutics to 50c from $1 and keeps a Neutral rating on the shares after the company received another complete response letter for ONS-5010. "This is not the first time that the company has misread FDA's feedback and what the Agency needed to approve ONS-5010," the analyst tells investors in a research note. H.C. Wainwright is not even sure there's much of a commercial opportunity for ONS-5010 anymore. It is concerned about the company's path forward.

Chardan

Daniil Gataulin

Neutral

downgrade

$3 -> $1

2026-01-02

Reason

Chardan

Daniil Gataulin

Price Target

$3 -> $1

2026-01-02

downgrade

Neutral

Reason

Chardan analyst Daniil Gataulin lowered the firm's price target on Outlook Therapeutics to $1 from $3 and keeps a Neutral rating on the shares. The company received a complete response letter from the FDA for Lytenava, Outlook's ophthalmic formulation of bevacizumab, in wet age-related macular degeneration, the analyst tells investors in a research note. The firm said this is yet another setback for the company following a CRL for Lytenava on August 28 and BLA resubmission shortly thereafter. While the news is disappointing, the firm said it is not surprised by the decision, as it believed the approval would be unlikely in the absence of additional studies.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OTLK

Unlock Now

H.C. Wainwright

Douglas Tsao

NULL -> Sell

downgrade

$3 -> $1

2025-08-29

Reason

H.C. Wainwright

Douglas Tsao

Price Target

$3 -> $1

2025-08-29

downgrade

NULL -> Sell

Reason

H.C. Wainwright analyst Douglas Tsao downgraded Outlook Therapeutics with a price target of $1, down from $3. The firm is \"disappointed \"that the FDA issued a complete response letter for ONS-5010 in wet age-related macular degeneration. It downgraded Outlook after removing all future U.S. revenues for ONS-5010 from its valuation.

Guggenheim

Buy

Neutral

downgrade

2025-08-29

Reason

Guggenheim

Price Target

2025-08-29

downgrade

Buy

Neutral

Reason

As previously reported yesterday, Guggenheim downgraded Outlook Therapeutics to Neutral from Buy and removed the firm's price target after the company received another complete response letter from the FDA regarding their BLA resubmission for ONS-5010 for the treatment of wetAMD. The firm, which previously thought there was "a small chance of approval," now has "serious doubts" on the company's ability to get ONS-5010 approved in the U.S.

About OTLK

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.